Boxer Capital Management LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)

Boxer Capital Management LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 250,000 shares of the company's stock, valued at approximately $3,958,000. Boxer Capital Management LLC owned 0.62% of Keros Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. MetLife Investment Management LLC lifted its position in Keros Therapeutics by 6.0% during the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock valued at $286,000 after acquiring an additional 1,027 shares during the period. Handelsbanken Fonder AB grew its stake in shares of Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after buying an additional 1,372 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Keros Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after acquiring an additional 2,462 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Trading Up 0.9 %

Shares of NASDAQ KROS opened at $14.57 on Friday. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The firm has a market capitalization of $591.70 million, a price-to-earnings ratio of -2.80 and a beta of 1.39. The firm has a 50 day moving average of $11.85 and a 200 day moving average of $26.64.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 22.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KROS. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research report on Thursday, January 16th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Finally, Piper Sandler decreased their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.